| Identification | Back Directory | [Name]
p38 MAP Kinase Inhibitor III | [CAS]
581098-48-8 | [Synonyms]
(S)-p38 MAPK Inhibitor III
(S)-p38 MAP Kinase Inhibitor III
p38 MAP Kinase Inhibitor III - CAS 581098-48-8 - Calbiochem
(S)-p-38 MAPK Inhibitor III,(S) p38 MAPK Inhibitor III,(S)p38 MAPK Inhibitor III
4-[5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl]-N-[(1S)-1-phenylethyl]-2-pyridinamine
2-Pyridinamine, 4-[5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl]-N-[(1S)-1-phenylethyl]- | [Molecular Formula]
C23H21FN4S | [MDL Number]
MFCD09037547 | [MOL File]
581098-48-8.mol | [Molecular Weight]
404.5 |
| Chemical Properties | Back Directory | [Melting point ]
117-119 °C | [Boiling point ]
589.4±60.0 °C(Predicted) | [density ]
1.30±0.1 g/cm3(Predicted) | [storage temp. ]
+2C to +8C | [solubility ]
DMF: 20 mg/mL; DMSO: 12 mg/mL; Ethanol: 30 mg/mL; Ethanol:PBS (pH 7.2)(1:2): 0.33 mg/mL | [form ]
Yellow solid | [pka]
9.07±0.10(Predicted) | [color ]
White to off-white | [InChI]
1S/C23H21FN4S/c1-15(16-6-4-3-5-7-16)26-20-14-18(12-13-25-20)22-21(27-23(28-22)29-2)17-8-10-19(24)11-9-17/h3-15H,1-2H3,(H,25,26)(H,27,28) | [InChIKey]
VXPWQNBKEIVYIS-UHFFFAOYSA-N | [SMILES]
Fc1ccc(cc1)c2[nH]c(nc2c3cc(ncc3)NC(C)c4ccccc4)SC |
| Hazard Information | Back Directory | [Description]
(S)-p38 MAPK inhibitor III is a methylsulfanylimidazole that inhibits p38 MAP kinase (IC50 = 0.90 μM in vitro). It is cell-permeable, potently blocking the release of TNF-α and IL-1β from human peripheral blood mononuclear cells (IC50s = 0.37 and 0.044 μM, respectively). | [Uses]
p38 MAP Kinase Inhibitor III (compound 7h) is a p38 MAPK inhibitor with an 50 of 0.9 μM. p38 MAP Kinase Inhibitor III also inhibits IL-1β and TNF-α release with 50 values of 0.37 μM and 0.044 μM, respectively[1]. | [General Description]
A cell-permeable methylsulfanylimidazole compound that acts as a potent, selective, reversible, and ATP-competitive p38 MAP kinase inhibitor (IC50 = 0.38 μM for p38α). Shown to effectively suppresses LPS-induced cytokine release both in vitro (IC50 = 0.16 and 0.039 μM for TNF-α and IL-1β release, respectively, in human PBMC) and in vivo (ED50 = 1.33 mg/kg for TNF-α release in mouse). When compared with SB 203580 (Cat. No. 559389 and 559398), it exhibits reduced inhibitory activity against cytochrome P450-2D6 isoform and, therefore, is better suited for in vivo use. A 10 mM (1 mg/247 μl) solution of p38 MAP Kinase Inhibitor III (Cat. No. 506148) in DMSO is also available. | [Biochem/physiol Actions]
Cell permeable: yes | [IC 50]
p38 MAP kinase: 0.9 μM (IC50) | [References]
[1] Stefan A Laufer, et al. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44. DOI:10.1021/jm030766k |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
| Company Name: |
Merck Millipore
|
| Tel: |
1-400-889-1988 400-889-1988 |
| Website: |
http://www.merckmillipore.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|